Drug Trial Radar · NCT06308861
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Aug 12, 2020
Primary completion
Jun 25, 2021
Study completion Jul 13, 2021
Sponsor
- Lead sponsor
- J2H BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2. Design: A dose block-randomized, double-blind, placebo controlled, single- and multiple dosing, dose-escalation phase 1 clinical trial
Conditions
- Non-alcoholic Steatohepatitis
Interventions
Single administration Amg dose GroupDrug
Orally, Amg tablet single administration
Single administration Bmg dose GroupDrug
Orally, Bmg tablet single administration
Single administration Cmg dose GroupDrug
Orally, Cmg tablet single administration
Single administration Dmg dose GroupDrug
Orally, Dmg tablet single administration
Single administration Emg dose GroupDrug
Orally, Emg tablet single administration
Single administration Amg dose Group-PlaceboDrug
Orally, Placebo Amg tablet, single administration
Single administration Bmg dose Group-PlaceboDrug
Orally, Placebo Bmg tablet, single administration
Single administration Cmg dose Group-PlaceboDrug
Orally, Placebo Cmg tablet, single administration
Single administration Dmg dose Group-PlaceboDrug
Orally, Placebo Dmg tablet, single administration
Single administration Emg dose Group-PlaceboDrug
Orally, Placebo Emg tablet, single administration
Multiple administration Amg dose groupDrug
Orally, Amg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Bmg dose groupDrug
Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Cmg dose groupDrug
Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Dmg dose groupDrug
Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Emg dose groupDrug
Orally, Emg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Amg dose group - PlaceboDrug
Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Bmg dose group - PlaceboDrug
Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Cmg dose group - PlaceboDrug
Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Dmg dose group - PlaceboDrug
Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Emg dose group - PlaceboDrug
Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours (After IP administration)
- EmaxTime frame: -1day 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours, 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours (After IP administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
J2H Biotech
Suwon, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.